清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Abstract 1217: Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors

西妥昔单抗 克拉斯 癌症研究 体内 内化 细胞毒性T细胞 化学 表皮生长因子受体 肿瘤微环境 单克隆抗体 医学 体外 癌症 结直肠癌 抗体 内科学 生物 受体 免疫学 生物化学 生物技术 肿瘤细胞
作者
Lei Huang,Bob Veneziale,Mark Frigerio,George O. Badescu,Xiao-ming Li,Qiping Zhao,Jesse D. Bahn,Jennifer Souratha,Ryan J. Osgood,Chun‐Mei Zhao,Kim B. Phan,Jessica Cowell,Sanna Rosengren,Jason Parise,Martin Pabst,Mathew Bird,William McDowell,Gina Wei,Curtis B. Thompson,Antony Godwin
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:76 (14_Supplement): 1217-1217 被引量:8
标识
DOI:10.1158/1538-7445.am2016-1217
摘要

Abstract Cancers with downstream activating KRAS or BRAF mutations in the EGFR pathway are resistant to EGFR targeting agents such as cetuximab and correspond to a significant unmet need. We hypothesized that an anti-EGFR ADC could be effective against KRAS or BRAF mutated tumors due to the cytotoxic mechanism of the ADC warhead. In an effort to eliminate the known dermal toxicity associated with anti-EGFR therapy, and to mitigate potential toxicities associated with treatment by an anti-EGFR ADC, a mAb was engineered with increased tumor microenvironment (TME) specificity for EGFR. The lead mAb demonstrated undetectable in vivo binding to human donor foreskins grafted onto nude mice, while binding to human A431 tumor xenografts with similar intensity to cetuximab (P < 0.005, detected using DyLight-755 conjugated versions of each mAb, measured with a Caliper IVIS system). The lead mAb was further optimized and conjugated to the potent cytotoxic drug MMAE using a novel bis-alkylating conjugation linker, which covalently re-bridged the inter-chain disulfide bonds, creating a stable and defined ADC. The resulting ADC, HTI-1511, incorporated a vc-PAB cleavable moiety and a short linear PEG (24 ethylene glycol units) in a side-chain configuration. Analytical HIC revealed that HTI-1511 possessed a nearly homogenous drug:antibody ratio (DAR) of 4 (>99.7%). Approximately 70% of this compound was rapidly internalized by human tumor cells grown in vitro over 4 hours, overlapping the internalization kinetics of the unconjugated mAb. HTI-1511 was evaluated for efficacy against two human EGFR overexpressing tumor models, MDA-MB-231M (triple-negative breast cancer, KRAS-G13D) and HT-29 (colorectal cancer, BRAF-V600E), and dosed at 5, 10, and 15 mg/kg, (qw, IV). A clear dose dependent anti-tumor response was observed with complete tumor regressions observed at the 15 mg/kg dose in both models, which were resistant to treatment by cetuximab. In addition, HTI-1511 was well-tolerated at 2 and 8 mg/kg in a cynomolgus monkey toxicity study (n = 3 per group), with limited dermal findings that were comparable with the vehicle control group. No adverse findings were observed at either dose. HTI-1511 showed a high degree of circulating stability in cynomolgus monkeys, and lacked in vivo degradation and instability that was observed in a control ADC conjugated using maleimide chemistry. HTI-1511 demonstrated significantly attenuated binding to FcγRIIa, FcγIIb, FcγIIIa 158V, and FcγIIIa 158F receptors, but not attenuated binding to FcγR1, in a FACS based assay format specific for each receptor, suggesting that HTI-1511 might have improved tolerability due to lack of binding by FcγRII-III receptors, possibly due steric hindrance from the PEG side chain. Thus, HTI-1511 holds promise as a potentially safe and effective treatment of EGFR overexpressing tumors with KRAS or BRAF mutations. Citation Format: Lei Huang, Bob Veneziale, Mark Frigerio, George Badescu, Xiaoming Li, Qiping Zhao, Jesse Bahn, Jennifer Souratha, Ryan Osgood, Chunmei Zhao, Kim Phan, Jessica Cowell, Sanna Rosengren, Jason Parise, Martin Pabst, Mathew Bird, William McDowell, Gina Wei, Curtis Thompson, Antony Godwin, Michael Shepard, Christopher Thanos. Preclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1217.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
愉快的书桃完成签到,获得积分10
16秒前
加油完成签到 ,获得积分10
27秒前
pigff完成签到,获得积分10
27秒前
系统昵称完成签到,获得积分10
35秒前
白白完成签到,获得积分10
37秒前
黑大侠完成签到 ,获得积分0
44秒前
如意大神完成签到,获得积分10
50秒前
武安发布了新的文献求助10
1分钟前
波波波波波6764完成签到 ,获得积分10
1分钟前
欢呼的听枫完成签到,获得积分10
1分钟前
狞风妖完成签到 ,获得积分10
1分钟前
syvshc的应助被科研通管家采纳,获得10
1分钟前
俭朴竺完成签到,获得积分10
1分钟前
超男完成签到 ,获得积分10
1分钟前
丰富凌晴完成签到,获得积分10
2分钟前
Ahui完成签到 ,获得积分10
2分钟前
优雅的梦芝完成签到,获得积分10
2分钟前
温柔的谷冬完成签到,获得积分10
2分钟前
2分钟前
ww发布了新的文献求助10
2分钟前
小伟跑位完成签到,获得积分10
3分钟前
满意的平凡完成签到,获得积分10
3分钟前
奥丁不言语完成签到 ,获得积分10
3分钟前
哈哈哈哈哈完成签到,获得积分10
3分钟前
n01W97的应助被科研通管家采纳,获得20
3分钟前
n01W97的应助被科研通管家采纳,获得20
3分钟前
3分钟前
勤奋笙的应助被科研通管家采纳,获得10
3分钟前
幽默绝悟完成签到,获得积分10
3分钟前
北鲲居士完成签到,获得积分10
4分钟前
qianci2009完成签到,获得积分0
4分钟前
甜蜜的紫菜完成签到,获得积分10
4分钟前
舒心的瑾瑜完成签到,获得积分10
4分钟前
失眠紫完成签到,获得积分10
4分钟前
mousfy完成签到 ,获得积分10
4分钟前
5分钟前
YuLu完成签到 ,获得积分10
5分钟前
谨慎小土豆完成签到,获得积分10
5分钟前
知性的夏槐完成签到 ,获得积分10
5分钟前
5分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834496
捐赠科研通 7783067
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558912
邀请新用户注册赠送积分活动 2481326